Sangamo BioSciences Inc. (NASDAQ:SGMO) shares fell 1.5% during trading on Monday . The company traded as low as $6.04 and last traded at $6.09, with a volume of 342,921 shares traded. The stock had previously closed at $6.18.

A number of research firms have recently commented on SGMO. Jefferies Group reissued a “buy” rating and set a $14.00 target price on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Wells Fargo & Co. began coverage on shares of Sangamo BioSciences in a research report on Tuesday, May 3rd. They set a “buy” rating on the stock. Zacks Investment Research cut shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Finally, Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Sangamo BioSciences in a research report on Friday, May 6th. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. Sangamo BioSciences currently has a consensus rating of “Buy” and an average price target of $16.75.

The company’s market cap is $422.95 million. The stock’s 50 day moving average is $6.25 and its 200-day moving average is $6.28.

Sangamo BioSciences (NASDAQ:SGMO) last issued its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business earned $3.94 million during the quarter, compared to analyst estimates of $5.49 million. Sangamo BioSciences’s revenue for the quarter was down 70.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.08) EPS. Equities analysts predict that Sangamo BioSciences Inc. will post ($0.98) EPS for the current fiscal year.

Several institutional investors have modified their holdings of SGMO. Royce & Associates LLC increased its position in shares of Sangamo BioSciences by 47.1% in the fourth quarter. Royce & Associates LLC now owns 312,100 shares of the biopharmaceutical company’s stock worth $2,849,000 after buying an additional 100,000 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Sangamo BioSciences by 26.6% in the fourth quarter. Wells Fargo & Company MN now owns 213,586 shares of the biopharmaceutical company’s stock worth $1,950,000 after buying an additional 44,875 shares in the last quarter. Numeric Investors LLC increased its position in shares of Sangamo BioSciences by 80.7% in the fourth quarter. Numeric Investors LLC now owns 148,969 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 66,519 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Sangamo BioSciences by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 128,941 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 2,257 shares in the last quarter.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.